■血液透析(HD)的终末期肾病(ESRD)患者有高钾血症(HK)的风险,与心律失常和猝死有关。关于中国HD患者的HK负担和管理技术的数据仍然很少。这项研究评估了治疗方式,复发,中国HD患者中HK的患病率。
在2021年5月至2022年7月进行的这项前瞻性队列研究中,来自中国15个中心(长达6个月)的年龄≥18岁的ESRD患者和HD患者。
■总的来说,纳入600例患者。在基线访问时,平均(±标准偏差)尿素减少率为68.0%±9.70,Kt/V为1.45±0.496。超过6个月,453名(75.5%)患者经历了香港,其中356人(78.6%)复发。在1、2、3、4、5和6个月内,203(44.8%),262(57.8%),300(66.2%),326(72.0%),347(76.6%),356例(78.6%)患者至少有一次香港复发事件,分别。≥1、2、3、4、5或6例HK复发事件的患者比例为356例(78.6%),306(67.5%),250(55.2%),208(45.9%),161(35.5%),和110(24.3%),分别。在453名经历过HK的患者中,只有24(5.3%)用钾粘合剂处理:7(1.5%)用聚苯乙烯磺酸钠处理,13(2.9%)与聚苯乙烯磺酸钙,和六(1.3%)用环硅酸锆钠。
■由于香港是一种慢性疾病,长期护理是必要的。HD患者应在非透析日进行有效的钾管理,然而,我们的现实世界人口很少使用钾粘合剂。
■ClinicalTrials.gov标识符NCT04799067。
UNASSIGNED: Patients with end-stage renal disease (ESRD) on hemodialysis (HD) are at risk for hyperkalemia (HK), associated with cardiac arrhythmia and sudden death. Data on the burden of HK and management techniques among HD patients in China are still scarce. This study assessed the treatment modalities, recurrence, and prevalence of HK in Chinese HD patients.
UNASSIGNED: In this prospective cohort study conducted from May 2021 to July 2022, patients aged ≥18 years who had ESRD and were on HD were enrolled from 15 centers in China (up to 6 months).
UNASSIGNED: Overall, 600 patients were enrolled. At the baseline visit, mean (± standard deviation) urea reduction ratio was 68.0% ± 9.70 and Kt/V was 1.45 ± 0.496. Over 6 months, 453 (75.5%) patients experienced HK, of whom 356 (78.6%) recurred. Within 1, 2, 3, 4, 5, and 6 months, 203 (44.8%), 262 (57.8%), 300 (66.2%), 326 (72.0%), 347 (76.6%), and 356 (78.6%) patients had at least one HK recurrence event, respectively. The proportions of patients with ≥1, 2, 3, 4, 5, or 6 HK recurrence events were 356 (78.6%), 306 (67.5%), 250 (55.2%), 208 (45.9%), 161 (35.5%), and 110 (24.3%), respectively. Among the 453 patients who experienced HK, only 24 (5.3%) were treated with potassium binders: seven (1.5%) with sodium polystyrene sulfonate, 13 (2.9%) with calcium polystyrene sulfonate, and six (1.3%) with sodium zirconium cyclosilicate.
UNASSIGNED: Since HK is a chronic illness, long-term care is necessary. Patients on HD should have effective potassium management on non-dialysis days, yet our real-world population rarely used potassium binders.
UNASSIGNED: ClinicalTrials.gov Identifier NCT04799067.